EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

LP‐003, a novel high‐affinity anti‐IgE antibody for inadequately controlled seasonal allergic rhinitis: A multicenter, randomized, double‐blind, placebo‐controlled phase 2 clinical trial

Kai Guan iD, Shuang Liu iD, Yan Feng iD, Lisha Li iD, Xiaoming Zhu, Nai-Chau-Sun Bill, Haili Ma, Jie Yang, Cuicui Han, Heng Liu, Qingyu Wei iD, Haiyun Shi iD und 1 weitere

Clinical and Translational Allergy · 2025-06 · 15 (6)

DOI: 10.1002/clt2.70074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Allergy, online erschienen am 22.06.2025. Verfasst von Kai Guan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment on Allergic Diseases, National Clinical Research Cent…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Longbio Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti‐IgE therapy can serve as an option for inadequately controlled seasonal allergic rhinitis (SAR) patients. LP‐003, a novel anti‐IgE antibody, is being tested as an add‐on treatment for SAR. This trial aimed to evaluate whether LP‐003 is effective and safe for SAR.

Methods

This placebo‐controlled double‐blind phase 2 randomized clinical trial was conducted in 17 hospitals in China. SAR patients whose symptoms were inadequately controlled despite first‐line treatment (nasal corticosteroids with or without oral antihistamine) in the previous two seasons were enrolled between July 6, 2023 and August 7, 2023. Participants were randomized in a ratio of 2:4:3 to receive subcutaneous injections of 100 mg LP‐003, 200 mg LP‐003 or placebo every 4 weeks for 2 doses. All patients received fluticasone propionate as standard‐of‐care (SoC). The main outcome was the mean total nasal symptom score (TNSS) during the peak pollen period (PPP). Secondary endpoints included a series of symptom and medication scores, quality of life assessments during PPP and pollen period (PP), immunogenicity and safety.

Results

A total of 180 participants were randomly assigned. The LP‐003 + SoC treatment achieved a significantly lower TNSS compared with placebo + SoC (3.31 vs. 4.06, intergroup difference = −0.74, p = 0.0464). For key secondary outcomes, the LP‐003 group also achieved significantly lower daily nasal symptom and rescue medication use scores (3.54 vs. 4.42, intergroup difference = −0.88, p = 0.0352), and daily ocular symptom and rescue medication use scores (1.66 vs. 2.19, intergroup difference = −0.54, p = 0.0245) compared to the placebo group. The suppression of free IgE was prevalent and persistent. There was no statistically significant difference in adverse events and severe adverse events between LP‐003 and placebo groups.

Conclusions

These findings support LP‐003 as a promising add‐on option to the SoC for patients with moderate to severe SAR. Fixed dosage regimen and extensive suppression of free‐IgE render it a cutting‐edge advantage.

Schlagwörter

Stichwörter der Autor:innen

RCTanti‐IgE antibodynasal symptomseasonal allergic rhinitisuncontrolled

Autor:innen und Institutionen

  • Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment on Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical Col…
  • Department of Otorhinolaryngology Head and Neck Surgery, Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Department of Allergy, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
  • Longbio Pharmaceutical Company, Suzhou, Jiangsu, China.
  • Department of Allergy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Kai Guan, Shuang Liu, Yan Feng, Lisha Li, Qingyu Wei, Haiyun Shi, Xueyan Wang

Förderung

  • Longbio Pharma

Zitieren

APA

Guan, K., Liu, S., Feng, Y., Li, L., Zhu, X., Bill, N. C., Ma, H., Yang, J., Han, C., Liu, H., Wei, Q., Shi, H., & Wang, X. (2025). LP‐003, a novel high‐affinity anti‐IgE antibody for inadequately controlled seasonal allergic rhinitis: A multicenter, randomized, double‐blind, placebo‐controlled phase 2 clinical trial. Clinical and Translational Allergy, 15(6). https://doi.org/10.1002/clt2.70074

Vancouver

Guan K, Liu S, Feng Y, Li L, Zhu X, Bill NC, et al. LP‐003, a novel high‐affinity anti‐IgE antibody for inadequately controlled seasonal allergic rhinitis: A multicenter, randomized, double‐blind, placebo‐controlled phase 2 clinical trial. Clinical and Translational Allergy. 2025;15(6). doi:10.1002/clt2.70074

BibTeX
@article{Guan2025,
  author = {Guan, Kai and Liu, Shuang and Feng, Yan and Li, Lisha and Zhu, Xiaoming and Bill, Nai-Chau-Sun and Ma, Haili and Yang, Jie and Han, Cuicui and Liu, Heng and Wei, Qingyu and Shi, Haiyun and Wang, Xueyan},
  title = {LP‐003, a novel high‐affinity anti‐IgE antibody for inadequately controlled seasonal allergic rhinitis: A multicenter, randomized, double‐blind, placebo‐controlled phase 2 clinical trial},
  journal = {Clinical and Translational Allergy},
  year = {2025},
  volume = {15},
  number = {6},
  doi = {10.1002/clt2.70074}
}
Kostenlos starten →